Abstract:Importance: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). Objectives: To compare clinical characteristics and treatment outcomes of torsemide vs furosemide in patients hospitalized with de novo HF vs WHF. Design, setting, and participants: All patients with a documented ejection fraction who were randomized in the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) trial, conducted from June 18 through March 2022, were included in this post hoc analysis. Study data were analyzed March to May 2023. Exposure: Patients were categorized by HF type and further divided by loop diuretic strategy. Main outcomes and measures: End points included all-cause mortality and hospitalization outcomes over 12 months, as well as change from baseline in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). Results: Among 2858 patients (mean [SD] age, 64.5 [14.0] years; 1803 male [63.1%]), 838 patients (29.3%) had de novo HF, and 2020 patients (70.7%) had WHF. Patients with de novo HF were younger (mean [SD] age, 60.6 [14.5] years vs 66.1 [13.5] years), had a higher glomerular filtration rate (mean [SD], 68.6 [24.9] vs 57.0 [24.0]), lower levels of natriuretic peptides (median [IQR], brain-type natriuretic peptide, 855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL), and tended to be discharged on lower doses of loop diuretic (mean [SD], 50.3 [46.2] mg vs 63.8 [52.4] mg). De novo HF was associated with lower all-cause mortality at 12 months (de novo, 65 of 838 [9.1%] vs WHF, 408 of 2020 [25.4%]; adjusted hazard ratio [aHR], 0.50; 95% CI, 0.38-0.66; P < .001). Similarly, lower all-cause first rehospitalization at 12 months and greater improvement from baseline in KCCQ-CSS at 12 months were noted among patients with de novo HF (median [IQR]: de novo, 29.94 [27.35-32.54] vs WHF, 23.68 [21.62-25.74]; adjusted estimated difference in means: 6.26; 95% CI, 3.72-8.81; P < .001). There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient-years]: torsemide, 27 [7.4%] vs furosemide, 38 [10.9%]; aHR, 0.70; 95% CI, 0.40-1.14; P = .15) or WHF (torsemide 212 [26.8%] vs furosemide, 196 [24.0%]; aHR, 1.08; 95% CI, 0.89-1.32; P = .42; P for interaction = .10), In addition, no significant differences in hospitalizations, first all-cause hospitalization, or total hospitalizations at 12 months were noted with a strategy of torsemide vs furosemide in either de novo HF or WHF. Conclusions and relevance: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.

Isolated systolic and diastolic ventricular interactions in pacing-induced dilated cardiomyopathy and effects of volume loading and pericardium.

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF)

The Role of Subcutaneous Furosemide in Heart Failure Management: A Systematic Review

Subcutaneous Furosemide: A Novel to Euvolemia

Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial

From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion

Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intra-patient Comparison of Three Diuretic Regimens (DEA-HF)

Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation

Comparison of three diuretic treatment strategies for patients with acute decompensated heart failure

Neurohormonal Effects of Intravenous Dopamine in Patients with Acute Heart Failure

[Efficacy and Safety of Azosemide in Patients with Edema and Ascites].

The dynamics of urine sodium concentration after intra-venous furosemide in patients with acute heart failure

Stable minimal cones in R^8 and R^9 with constant scalar curvature

Parental smoking and children’s respiratory health: independent effects of prenatal and postnatal exposure

Experimental observation of localized luminescence clamping in complex-coupled DFB laser diodes

Analysis Of Subcutaneous Furosemide Dosing Patterns And Impact On SCr And K+ In The Freedom-HF And AT HOME Studies

Treatment of Acute Decompensated Chronic Heart Failure: Furosemide vs Furosemide and Metolazone: A Cross-Sectional Comparative Study

Loop diuretic down‐titration at discharge in patients hospitalized for acute heart failure

Relationship between clinical congestion and worsening renal function after intravenous initiation of furosemide in patients with acute heart failure

Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial

Effects of a diuretic adjustment algorithm protocol on heart failure admissions: A randomized clinical trial